COMPANY

Cognition Therapeutics

Cognition is advancing the development of an oral medication – zervimesine (also CT1812) – to treat these diseases. From company website Source · Oct 13, 2026

Keywords: small molecule Alzheimer Disease Dementia With Lewy Bodies Early Alzheimer's Disease Mild to Moderate Alzheimer's Disease Age-Related Macular Degeneration Alzheimer's Disease Cognitive Impairment CT1812 Active Comparator CT1812

Location: Purchase, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

$30.0MRaised (2 yrs)13Trials (company is sponsor)

Funding and NIH signals

NIH award NIH awarded $16.49M (NIH grant 5R01AG065248-05, continuation, notice Aug 25, 2026). NIH RePORTER 5R01AG065248-05 (Aug 25, 2026)
Evidence (1 event)
- Aug 25, 2026 · NIH RePORTER 5R01AG065248-05
  Organization: COGNITION THERAPEUTICS, INC.; City/State: PITTSBURGH, PA; Project number: 5R01AG065248-05; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 16494670; Administering IC: National Institute on Aging; Project title: Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Undisclosed round · $30M · announced Sep 2, 2025 Company release ↗
Source quote
- Sep 2, 2025 · Company release ↗
  “Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)”

Raises announced in these releases: $30M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Aug 25, 2026 Grant Government grant — NIH R01: $16.49M (annual award, as published), announced Aug 25, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 2, 2025 Raise Follow-on offering — Registered direct: $30M (total, as published), announced Sep 2, 2025. Source: company release on GlobeNewswire. source ↗
Sep 2, 2025 Raise Undisclosed round · $30M source ↗
Jul 28, 2025 Grant Government grant — NIH R01: $11.96M (annual award, as published), announced Jul 28, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Jun 28, 2023 Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease source ↗
Jun 16, 2023 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). source ↗
May 19, 2022 Trial start Phase 2: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies source ↗
Feb 15, 2022 Trial start Phase 1: Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers source ↗
Dec 31, 2021 Trial start Phase 1: Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects source ↗
Jul 9, 2020 Trial start Phase 2: Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG source ↗
Oct 10, 2018 Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. source ↗
May 30, 2018 Trial start Phase 1: Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease source ↗
Mar 28, 2018 Trial start Phase 1/Phase 2: Effect of CT1812 Treatment on Brain Synaptic Density source ↗
Nov 10, 2016 Trial start Phase 1: Drug Interaction Study of CT1812 in Healthy Volunteers source ↗
2016-09 Trial start Phase 1/Phase 2: Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease source ↗
2015-09 Trial start Phase 1: Ascending Dose Study of CT1812 in Healthy Volunteers source ↗

Upcoming milestones

May 31, 2027 (ESTIMATED) · Phase 2 · A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease · NCT05531656

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $30.0M. Last 2 years.

Sep 2, 2025 Follow-on offering — Registered direct: $30M (total, as published), announced Sep 2, 2025. Source: company release on GlobeNewswire. source ↗
Aug 25, 2026 Government grant — NIH R01: $16.49M (annual award, as published), announced Aug 25, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Jul 28, 2025 Government grant — NIH R01: $11.96M (annual award, as published), announced Jul 28, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT05531656	A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease	Phase 2	Active, not recruiting	Jun 28, 2023	May 31, 2027 (estimated)
NCT06961760	Expanded Access Program for CT1812 (Zervimesine)	Not listed	No longer available	Not listed	Not listed
NCT05225415	Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies	Phase 2	Completed	May 19, 2022	Nov 25, 2024 (actual)
NCT03507790	A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.	Phase 2	Completed	Oct 10, 2018	May 29, 2024 (actual)
NCT05893537	Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).	Phase 2	Terminated	Jun 16, 2023	Mar 4, 2025 (actual)
NCT04735536	Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG	Phase 2	Completed	Jul 9, 2020	Apr 26, 2023 (actual)
NCT03493282	Effect of CT1812 Treatment on Brain Synaptic Density	Phase 1/Phase 2	Completed	Mar 28, 2018	Oct 16, 2020 (actual)
NCT05225389	Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects	Phase 1	Completed	Dec 31, 2021	Jan 17, 2022 (actual)
NCT05248672	Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers	Phase 1	Completed	Feb 15, 2022	Jun 1, 2022 (actual)
NCT03522129	Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease	Phase 1	Completed	May 30, 2018	Feb 6, 2019 (actual)
NCT03716427	Drug Interaction Study of CT1812 in Healthy Volunteers	Phase 1	Completed	Nov 10, 2016	Dec 27, 2016 (actual)
NCT02907567	Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease	Phase 1/Phase 2	Completed	2016-09	Aug 24, 2017 (actual)
NCT02570997	Ascending Dose Study of CT1812 in Healthy Volunteers	Phase 1	Completed	2015-09	2016-05 (actual)